Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
4 - Bipolar Disorder and Mood Stabilizers
Published online by Cambridge University Press: 19 October 2021
Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Stahl's Self-Assessment Examination in PsychiatryMultiple Choice Questions for Clinicians, pp. 149 - 196Publisher: Cambridge University PressPrint publication year: 2019
References
References
Berk, M, Kapczinski, F, Andreazza, AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress, and neurotrophic factors. Neurosci Biobehav Rev 2011;35(3): 804–17.1Google Scholar
Kapczinksi, F, Vieta, E, Andreazza, AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675–92.2Google Scholar
Post, RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007;31:858–73.3Google Scholar
References
Bachman, RF, Wang, Y, Yuan, P et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009;12:805–22.1CrossRefGoogle Scholar
Berk, M, Kapczinski, F, Andreazza, AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress, and neurotrophic factors. Neurosci Biobehav Rev 2011;35(3): 804–17.2CrossRefGoogle ScholarPubMed
Hunsberger, J, Austin, DR, Henter, ID, Chen, G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009;11(3):333–48.3Google Scholar
References
Galbally, M, Snellen, M, Power, J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Therapeutic Adv Drug Safety 2014;5(2):100–9.1Google Scholar
Gentile, S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36(3):518–44.2Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology: the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.3Google Scholar
Yacobi, S, Ornoy, A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008;45(2):95–106.4Google ScholarPubMed
References
Nivoli, AMA, Colom, F, Murru, A et al. New treatment guidelines for acute bipolar depression. A systematic review. J Affect Disord 2010;129:14–26.1CrossRefGoogle ScholarPubMed
Selle, V, Schalkwijk, S, Vazquez, GH, Baldessarini, RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014;47(2):43–52.2Google ScholarPubMed
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 8)1Google Scholar
Stahl, SM. Essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
References
Angst, J, Azorin, JM, Bowden, CL et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68(8):791–9.1Google Scholar
Dervic, K, Garcia-Amador, M, Sudol, K et al. Bipolar I and II versus unipolar depression: clinical differences and impulsivity/aggression traits. Eur Psychiatry 2015;30(1):106–13.2CrossRefGoogle ScholarPubMed
References
Sitges, M, Chiu, LM, Guarneros, A, Nekrassov, V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate, and vinpocetine on NA+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 2007;52(2):598–605.1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 8)2Google Scholar
References
Chu, CT, Chuang, DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010;128:281–304.1CrossRefGoogle Scholar
Pasquali, L, Busceti, CL, Fulceri, F, Paparelli, A, Fornai, F. Intracellular pathways underlying the effects of lithium. Behav Pharmacol 2010;21: 473–92.2Google Scholar
Quiroz, JA, Machado-Vieira, R, Zarate, CA Jr, Manji, HK. Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010;62:50–60.3CrossRefGoogle ScholarPubMed
References
Grandjean, EM, Aubry, JM. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009;23(4):331–49.1CrossRefGoogle ScholarPubMed
McKnight, RF, Adida, M, Budge, K et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721–8.2CrossRefGoogle ScholarPubMed
References
Kroeze, WK, Hufeisen, SJ, Popadak, BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519–26.1Google ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapters 5, 8)2Google Scholar
Stahl, SM, Mignon, L. Stahl’s illustrated antipsychotics, second edition. New York, NY: Cambridge University Press; 2009.3Google Scholar
References
Miller, S, Suppes, T, Mintz, J et al. Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow-up in the Stanley Bipolar Network. Am J Psychiatry 2016;173(10):1015–23.1Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 5)1Google Scholar
Stahl, SM. Essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
References
McIntyre, RS, Lee, Y, Mansur, RB. A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. CNS Spectr 2016;21:28–32.1Google Scholar
Stahl, SM. Essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
Stahl, SM, Morrissette, DA, Faedda, G et al. Guidelines for the recognition and treatment of mixed depression. CNS Spectr 2017;22(2): 203–19.3Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 8)1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
References
Koukopoulos, A, Sani, G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand 2014;129:4–16.1CrossRefGoogle ScholarPubMed
Mahli, GS, Laampe, L, Coulston, CM et al. Mixed state discrimination: a DSM problem that won’t go away? J Affective Disord 2014;158:8–10.2Google Scholar
Takeshima, M, Oka, T. DSM-5-defined ‘mixed features’ and Benazzi’s mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression? Psychiatry Clin Neurosci 2015;69(2):109–16.3Google Scholar
References
Aia, PG, Reveulta, GJ, Cloud, LJ, Factor, SA. Tardive dyskinesia. Curr Treatment Options Neurol 2011;13(3):231–41.1Google Scholar
Moseley, CN, Simpson-Khanna, HA, Catalano, G, Catalano, MC. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clin Neuropharmacol 2013;36(4):128–30.2Google Scholar
Umbrich, P, Soares, KV. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003;(2):CD000205.3Google Scholar
References
Stahl, SM. Essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.1Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.1Google Scholar
References
Elliot, R, Ogilvie, A, Rubinsztein, JS, Calderon, G et al. Abnormal ventral frontal response during performance of an affective go/no go task in patients with mania. Biol Psychiatry 2004;155(12):1163–70.1Google Scholar
Price, JL, Drevets, WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010;35(1):192–216.2Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 6)3Google Scholar
References
Stahl, SM, Morrissette, DA, Faedda, G et al. Guidelines for the recognition and management of mixed depression. CNS Spectrums 2017;22(2):203–19.1Google Scholar
References
Koukopoulos, A, Sani, G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand 2014;129:4–16.1CrossRefGoogle ScholarPubMed
Mahli, GS, Laampe, L, Coulston, CM et al. Mixed state discrimination: a DSM problem that won’t go away? J Affective Disord 2014;158:8–10.2Google Scholar
Takeshima, M, Oka, T. DSM-5-defined ‘mixed features’ and Benazzi’s mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression? Psychiatry Clin Neurosci 2015;69(2):109–16.3CrossRefGoogle ScholarPubMed